Marker Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Net Income	-10.73	-8.24	-29.93	-41.88	-28.71	Upgrade
Depreciation & Amortization	-	-	-	3.16	1.08	Upgrade
Stock-Based Compensation	0.25	0.86	3.3	5.96	5.23	Upgrade
Other Operating Activities	-	-	-0.28	-	-0.03	Upgrade
Change in Accounts Receivable	-1.32	1.37	-2.4	1	0.06	Upgrade
Change in Accounts Payable	0.01	0.61	-1.32	4.14	3.05	Upgrade
Change in Unearned Revenue	-	-	-1.15	1.15	-	Upgrade
Change in Other Net Operating Assets	0.89	0.86	0.1	-0.82	-0.7	Upgrade
Operating Cash Flow	-10.91	-16.44	-26.97	-27.28	-20.03	Upgrade
Capital Expenditures	-	-	-	-3.13	-9.25	Upgrade
Other Investing Activities	-	18.66	-4.95	-	-	Upgrade
Investing Cash Flow	-	18.66	-4.95	-3.13	-9.25	Upgrade
Issuance of Common Stock	14.99	1.11	0.2	52.56	6.74	Upgrade
Financing Cash Flow	14.99	1.11	0.2	52.56	6.74	Upgrade
Net Cash Flow	4.08	3.33	-31.72	22.14	-22.55	Upgrade
Free Cash Flow	-10.91	-16.44	-26.97	-30.41	-29.29	Upgrade
Free Cash Flow Margin	-165.53%	-496.51%	-767.66%	-2449.11%	-6274.32%	Upgrade
Free Cash Flow Per Share	-1.22	-1.87	-3.23	-3.98	-6.23	Upgrade
Levered Free Cash Flow	-7.37	-10.14	-14.77	-12.98	-18.25	Upgrade
Unlevered Free Cash Flow	-7.37	-10.14	-14.77	-12.98	-18.25	Upgrade
Change in Net Working Capital	0.42	1.89	5.71	-5.7	-2.75	Upgrade

Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q